GMP News - Blood / Biologics and ATMP

19.09.13

World Health Organisation (WHO) continues successful collaboration with Paul-Ehrlich-Institut

WHO and PEI - eight years of successful cooperation for Quality Assurance of Blood Products and in vitro Diagnostic Devices. Read more here.

more

19.09.13

EMA Guideline on Quality of biological active Substances produced by transgene Expression in Animals

In May, the Committee for Medicinal Products for Human Use (CHMP) adopted the Guideline on Quality of biological active substances produced by transgene expression in animals. Read more.

more

19.09.13

Draft Guidance with Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products

Referring to the increasing need of Cellular and Gene Therapy products, the FDA published a daft guideline "Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products". More details can be found here.

more

27.08.13

EMA Guideline Guideline on the use of bovine serum in the manufacture of human biological medicinal products

The EMA Guideline on the use of bovine serum in the manufacture of human biological medicinal products will come into effect at the end of 2013. Read more here.

more

27.08.13

FDA publishes Guidance for Industry: Blood Establishment Computer System Validation in the User's Facility

Computer validation will be an important topic for blood establishments too. The US FDA published a guideline on that topic in March 2013. Read more here.

more

27.08.13

FDA Scientists link transfused UVB irradiated platelets with acute lung injury

Scientists at the U.S. Food and Drug Administration (FDA) have reported that studies performed in animals provide a proof of a concept that transfused UV-light damaged PLTs can mediate lung injury. Read more.

more

11.07.13

Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture

Related to changes to an approved application of human blood and blood components intended for transfusion or further manufacture, the FDA published a draft guidance for comment. Read more here.

more

11.07.13

FDA Safety Communication: New boxed warning for thrombosis related to human immune globulin products.

The US FDA has conducted retrospective analyses of data from a large health claims-related database as well as continued postmarketing adverse event reports of thrombosis. These analyses have strengthened the evidence for an association between the use of intravenous, subcutaneous, and intramuscular human immune globulin products and the risk of thrombosis. For that reason the authority now demands a boxed warning for the entire class of products. Read more.

more

21.03.13

Safety of Blood Components for Transfusion and of Stem Cell Products: Testing for HIV, HBV and HCV

In February, the Paul-Ehrlich-Institut published a  notification on "Imposition of conditions pursuant to Section 28 (3) c AMG (Arzneimittelgesetz, German Medicines Act) for the purpose of risk prevention to assure the safety of blood components for transfusion and of stem cell products for haematopoetic reconstitution: Testing for HIV, HBV and HCV". Read more.

more

21.03.13

FDA Recommendations for Syphilis Screening of Blood and Blood Components

In March 2013, the FDA published a draft guidance "Recommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis". For more details read here.

more

21.03.13

Technical Update of Inspection of Licensed and Unlicensed Blood Banks, Brokers, Reference Laboratories, and Contractors

The FDA updated the ongoing Chapter 42 - Blood and Blood Products Inspection of Licensed and Unlicensed Blood Banks, Brokers, Reference Laboratories, and Contractors- 7342.001 of the Compliance Program Guidance Manual. Get more details.

more

18.02.13

Starting Materials and Intermediates

In the European pharmaceutical legislation, requirements are outlined for particulars and documents that should accompany an application for marketing authorisation of a biological medicinal product. This includes information related to starting and raw materials. The draft reflection paper on the use of starting materials and intermediates collected from different sources in the manufacturing of biological medicinal products i supposed to provide information on that topic. Read more here.

more

18.02.13

Risk-based Approach to Advanced Therapy Medicinal Products

In 2012, the EMA Draft guideline on the risk-based approach according to Annex I, part IV of Directive 2001/83/EC applied to Advanced Therapy Medicinal Products was open for comments. The risk-based approach is based on the identification of various risks associated with the clinical use of an ATMP and risk factors inherent to the ATMP with respect to quality, safety and efficacy. To learn more about this, click here.

more

18.02.13

Warning on transmissible Agents

When medicinal products prepared from human blood or plasma are administered, infectious diseases due to the transmission of infective agents cannot be totally excluded. The "Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and package leaflets for plasma-derived medicinal products" updates the previous recommendations and states the warning to be included in the SmPC and Package Leaflet of any plasma-derived medicinal product. More details can be found here.

more

18.02.13

Isolation of Candidate Influenza Vaccine Viruses in Cell Culture

In Febraury 2012 EMA's "Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture" became official. The scope of this document is to provide guidance for the isolation on cell culture of any potential influenza vaccine virus intended for cell culture or egg-based influenza vaccine manufacture. More details can be found here.

more

GMP Newsletter

Sign up for the free of charge newsletters.

Sign up now!

GMP Conferences by Topics